Hercules Capital
Hercules Capital is a capital market company that lends to technology, life sciences, and sustainable technology companies.
Business Model:
Revenue: $294M
Employees: 51-200
Rankings
Detailed Hercules Capital Information
Geographic Data
Address: 400 Hamilton Avenue
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$7M
Raised Total:$7M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,157,853Website Global Rank
5,147Website Monthly Traffic
Twitter Followers
Description
Hercules is the largest non-bank lender to venture capital-backed companies at all stages of development in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience in venture debt, Hercules is uniquely positioned to quickly create innovative financing solutions that perfectly fit within a company&s;s existing capital structure and map to its business objectives. Recognized as the industry leader, Hercules understands the flexibility these types of companies need and has the experience to work closely with them, even through challenging times, to help them reach critical milestones. Hercules&s; deep sector expertise, geographic presence and its strong capital base have made Hercules the lender of choice for more than 480 innovative companies.
Contact Phone:
+16502893060
Contact Email:
Hercules Capital went public on 5/4/2012 on the NYSE
Listed Exchange:
NYSE
IPO Date:
5/4/2012
Ticker Symbol:
HTGC
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | SingleStore | Series E | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 80M |
| 5/2005 | WageWorks | Debt Financing | 20M |
| 2/2008 | Mode Media | Debt Financing | 20M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 2/2015 | SparkPost | Series C | 27M |
| 7/2015 | Gynesonics | Venture Round | 43M |
| 10/2005 | AGEIA Technologies | Series C | 27.5M |
| 6/2015 | Zosano Pharma | Post-IPO Debt | 15M |
| 10/2022 | Tricida | Post-IPO Debt | 125M |
| 5/2020 | SingleStore | Debt Financing | 50M |
| 10/2011 | BrightSource Energy | Debt Financing | 35M |
| 11/2022 | Kura Oncology | Post-IPO Debt | 125M |
| 6/2020 | G1 Therapeutics | Post-IPO Debt | 100M |
| 7/2006 | BabyUniverse, Inc. | Post-IPO Debt | 5M |
| 12/2013 | AcelRx Pharmaceuticals | Post-IPO Debt | 40M |
| 8/2020 | UNITY Biotechnology | Post-IPO Debt | 80M |
| 9/2021 | Phathom Pharmaceuticals | Post-IPO Debt | 200M |
| 5/2010 | Alexza Pharmaceuticals | Post-IPO Debt | 15M |
| 1/2008 | Rise Broadband | Venture Round | 15M |
| 2/2020 | ZeroFOX | Series D | 74M |
| 2/2015 | Agile Therapeutics | Post-IPO Debt | 25M |
| 7/2016 | Auris Medical | Post-IPO Debt | 12.5M |
| 10/2017 | Myovant Sciences | Post-IPO Debt | 40M |
| 7/2012 | Virident Systems | Venture Round | 5.7M |
| 6/2005 | Merrimack Pharmaceuticals | Debt Financing | 9M |
| 3/2007 | Memory Pharmaceuticals | Post-IPO Debt | 10M |
| 11/2012 | CapLinked | Series A | 0 |
| 10/2021 | Eloxx | Post-IPO Debt | 30M |
| 8/2012 | Fortress Biotech | Post-IPO Debt | 15M |
| 1/2006 | Xillix | Debt Financing | 5.5M |
| 3/2012 | Alphabet Energy | Debt Financing | 2M |
| 5/2010 | AVEO Oncology | Post-IPO Equity | 25M |
| 12/2006 | Nexx Systems | Debt Financing | 10M |
| 12/2005 | Cradle Technologies | Series E | 0 |
| 3/2019 | Aldeyra Therapeutics | Post-IPO Debt | 60M |
| 3/2009 | RazorGator | Debt Financing | 10M |
| 8/2005 | Adiana | Series D | 23M |
| 7/2007 | SiCortex | Debt Financing | 10M |
| 5/2006 | OATSystems | Debt Financing | 6M |
| 7/2007 | Prism Career Institute | Debt Financing | 3M |
| 6/2007 | Panacos Pharmaceuticals | Post-IPO Debt | 20M |
| 8/2006 | NOVASYS MEDICAL | Debt Financing | 8M |
| 3/2013 | NeuralStem | Post-IPO Debt | 8M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 8/2022 | Alladapt Immunotherapeutics | Debt Financing | 50M |
| 2/2015 | Message Systems | Debt Financing | 27M |
| 3/2019 | FuelCell Energy | Post-IPO Debt | - |
| 12/2012 | Comverge | Debt Financing | 34M |
| 8/2015 | Modumetal | Venture Round | 33.5M |
| 3/2005 | RazorGator | Series A | 26M |
| 6/2014 | Nanotherapeutics | Debt Financing | 30M |
| 4/2006 | Sirtris Pharmaceuticals | Debt Financing | - |
| 3/2007 | PSS Systems | Debt Financing | 5M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 5/2018 | CloudPay | Equity | 25M |
| 2/2016 | Aria Systems | Series E | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 80M |
| 7/2014 | SINTX Technologies | Post-IPO Debt | 0 |
| 7/2022 | IVERIC bio | Post-IPO Debt | 250M |
| 1/2013 | ADMA Biologics | Debt Financing | 6M |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 11/2014 | Flowonix | Venture Round | 20M |
| 4/2016 | ClearObject | Series E | 0 |
| 10/2007 | Diomed Holdings | Debt Financing | 10M |
| 12/2021 | Carwow | Debt Financing | 54.8M |
| 8/2021 | Better Therapeutics | Debt Financing | 50M |
| 1/2019 | Mesoblast | Post-IPO Debt | 75M |
| 8/2022 | ATAI Life Sciences | Post-IPO Debt | 175M |
| 11/2012 | NuPathe | Post-IPO Debt | 8.5M |
| 1/2023 | AmplifyBio | Debt Financing | 50M |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 2/2015 | Melinta Therapeutics | Post-IPO Debt | 30M |
| 3/2006 | Market Force Information | Debt Financing | 8M |
| 1/2006 | Acceleron Pharma | Debt Financing | 8M |
| 1/2015 | Aspire Bariatrics, Inc. | Debt Financing | 12M |
| 10/2014 | Gamma Medica | Series B | 0 |
| 3/2006 | RazorGator | Series B | 22.8M |
| 5/2012 | kaleo | Debt Financing | 15M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 6/2014 | Celator Pharmaceuticals | Debt Financing | 15M |
| 12/2007 | E-Band Communications | Series B | 10M |
| 2/2022 | Esme Learning Solutions | Venture Round | 15M |
| 11/2022 | Phathom Pharmaceuticals | Post-IPO Debt | 40M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 70M |
| 2/2019 | TG Therapeutics | Post-IPO Debt | 60M |
| 10/2021 | Locus Biosciences | Debt Financing | 25M |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 250M |
| 12/2005 | Guava Technologies | Debt Financing | 10M |
| 10/2006 | Atrenta | Venture Round | 0 |
| 11/2022 | Oak Street Health | Post-IPO Debt | 300M |
| 10/2022 | Automation Anywhere | Debt Financing | 200M |
| 6/2005 | Sling Media | Debt Financing | 4M |
| 4/2014 | Neos Therapeutics | Debt Financing | 20M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 12/2005 | Cornice | Series C | 97M |
| 11/2022 | Locus | Series F | 0 |
| 9/2016 | Druva | Series E | 51M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 2/2023 | Skydio | Series E | 0 |
| 12/2013 | ViewRay | Venture Round | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 5/2007 | Intelliden | Series E | 10M |
| 6/2015 | Proterra | Debt Financing | 25M |
| 6/2009 | Kamada | Venture Round | 20M |
| 3/2006 | Compete, Inc. | Venture Round | 4M |
| 3/2010 | InfoLogix | Venture Round | 3M |
| 8/2016 | Mattersight | Post-IPO Debt | 30M |
| 6/2013 | Rockwell Medical | Post-IPO Debt | 20M |
| 7/2018 | Merrimack Pharmaceuticals | Post-IPO Debt | 25M |
| 10/2022 | Replimune Group | Post-IPO Debt | 200M |
| 3/2021 | Humanigen | Post-IPO Debt | 80M |
| 12/2014 | Dynavax Technologies | Debt Financing | 40M |
| 9/2021 | Corium International | Debt Financing | 235M |
| 6/2017 | Concert Pharmaceuticals | Post-IPO Debt | 30M |
| 7/2018 | Acacia Pharma | Debt Financing | 30M |
| 7/2007 | Purcell Systems | Venture Round | 15M |
| 10/2020 | Bicycle Therapeutics | Debt Financing | 50M |
| 6/2005 | Labopharm | Debt Financing | 10M |
| 5/2018 | Asensus Surgical | Post-IPO Debt | 40M |
| 4/2007 | Everyday Health Group | Debt Financing | 8M |
| 11/2007 | Zayo | Debt Financing | 85M |
| 9/2021 | 3Gtms | Private Equity Round | 0 |
| 10/2008 | Blurb | Debt Financing | 2.5M |
| 11/2014 | nContact Surgical | Debt Financing | 20M |
| 2/2015 | SparkPost | Debt Financing | 8M |
| 7/2014 | UniQure | Post-IPO Debt | 20M |
| 1/2015 | MELA Sciences | Post-IPO Debt | 10M |
| 2/2019 | Urovant Sciences | Debt Financing | 100M |
| 7/2016 | Aprecia Pharmaceuticals | Debt Financing | 30M |
| 4/2016 | FuelCell Energy | Post-IPO Debt | 25M |
| 12/2014 | SOASTA | Debt Financing | 15M |
| 2/2010 | Propel Fuels | Debt Financing | 8M |
| 11/2013 | Celsion | Post-IPO Debt | 20M |
| 3/2016 | Mast Therapeutics | Post-IPO Debt | 15M |
| 12/2007 | Shocking Technologies | Debt Financing | 4M |
| 4/2007 | IKANO Communications | Post-IPO Debt | 22.5M |
| 3/2010 | Velocity Technology Solutions | Debt Financing | 25M |
| 8/2022 | Provention Bio | Post-IPO Debt | 125M |
| 10/2022 | Bright Machines | Debt Financing | 0 |
| 3/2017 | 908 Devices | Debt Financing | - |
| 8/2007 | Quartics | Venture Round | 7.5M |
| 8/2020 | AVEO Oncology | Post-IPO Debt | 35M |
| 7/2013 | BioAmber | Post-IPO Debt | 25M |
| 12/2018 | Contentful | Series D | 33.5M |
| 9/2014 | ChromaDex | Post-IPO Debt | 5M |
| 11/2012 | TransMedics | Venture Round | 36M |
| 1/2011 | Anthera Pharmaceuticals | Post-IPO Debt | - |
| 10/2013 | Cleveland BioLabs | Post-IPO Debt | 10M |
| 2/2014 | ADMA Biologics | Post-IPO Debt | 15M |
| 10/2006 | IWatt | Venture Round | 7M |
| 1/2006 | Optovia Corporation | Debt Financing | 5M |
| 1/2008 | Kadoink | Debt Financing | 2.5M |
| 4/2018 | Dashlane | Debt Financing | 10M |
| 4/2019 | Dashlane | Debt Financing | 30M |
| 6/2015 | Proterra | Series D | 55M |
| 1/2012 | Clustrix | Debt Financing | 4M |
| 11/2007 | WildTangent | Debt Financing | 20M |
| 5/2015 | ReachLocal | Post-IPO Debt | 25M |
| 1/2006 | Simpler Networks | Debt Financing | 10M |
| 6/2010 | BuyerLink | Venture Round | 15M |
| 8/2017 | BioQ Pharma | Debt Financing | - |
| 12/2005 | Atrenta | Venture Round | 10M |
| 9/2007 | Crux Biomedical | Venture Round | 250k |
| 1/2015 | Cerulean Pharma | Post-IPO Debt | 26M |
| 2/2017 | Sio Gene Therapies | Post-IPO Debt | 55M |
| 11/2020 | Udacity | Debt Financing | 75M |
| 5/2007 | Neosil | Debt Financing | 10M |
| 7/2017 | Sebacia | Debt Financing | 16M |
| 5/2006 | GameLogic | Debt Financing | 3M |
| 1/2015 | Bellicum Pharmaceuticals | Post-IPO Debt | - |
| 6/2012 | AMSC | Post-IPO Debt | 10M |
| 4/2014 | Alimera Sciences | Post-IPO Debt | 35M |
| 3/2005 | Omrix Biopharmaceuticals | Venture Round | 4.8M |
| 5/2021 | SCYNEXIS | Post-IPO Debt | 60M |
| 6/2005 | Sportvision | Debt Financing | 4M |
| 6/2013 | Anacor Pharmaceutical | Post-IPO Debt | 45M |
| 5/2014 | Medrobotics | Series E | 26M |
| 5/2015 | Machine Zone | Debt Financing | - |
| 2/2006 | HighRoads | Debt Financing | 2.5M |
| 4/2007 | Rubicon Technology | Post-IPO Debt | 16M |
| 11/2006 | Elixir Pharmaceuticals | Debt Financing | 15M |
| 4/2007 | NuGEN Technologies | Debt Financing | 3M |
| 8/2010 | Calera | Venture Round | 15M |
| 12/2007 | hi5 | Debt Financing | 15M |
| 6/2014 | CareCloud Corporation | Debt Financing | 25.5M |
| 8/2006 | Agami System | Debt Financing | 11M |
| 9/2014 | Edge Therapeutics | Debt Financing | 10M |
| 3/2005 | Inxight Software | Debt Financing | 5M |
| 1/2007 | Blurb | Debt Financing | 2.5M |
| 6/2016 | Plug Power | Post-IPO Debt | 70M |
| 2/2016 | CytRx | Post-IPO Debt | 40M |
| 8/2021 | Novelion Therapeutics | Post-IPO Debt | 50M |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 12/2013 | CTI BioPharma | Post-IPO Debt | 5M |
| 4/2018 | RumbleON | Post-IPO Debt | 15M |
| 3/2018 | Tricida | Debt Financing | 100M |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 12/2018 | Nabriva Therapeutics | Post-IPO Debt | 75M |
| 4/2014 | JumpStart | Debt Financing | 13M |
| 3/2013 | Medrobotics | Debt Financing | 10M |
| 3/2017 | Verastem Oncology | Post-IPO Debt | 25M |
| 4/2010 | PolyMedix | Post-IPO Equity | 14M |
| 5/2010 | Chroma Therapeutics | Debt Financing | 15M |
| 5/2021 | HiberCell | Debt Financing | 30M |
| 3/2019 | Constellation Pharmaceuticals | Post-IPO Debt | 40M |
| 10/2005 | Affinity Express | Venture Round | 3M |
| 5/2009 | E-Band Communications | Series C | - |
| 12/2014 | MELA Sciences | Post-IPO Debt | 20M |
| 3/2016 | Quanterix | Series D | 46M |
| 4/2007 | Tectura | Debt Financing | 22M |
| 11/2020 | CloudBolt | Debt Financing | 20M |
| 3/2018 | Metalysis | Venture Round | 16.9M |
| 12/2014 | ADMA Biologics | Post-IPO Debt | 5M |
| 12/2013 | Baxano Surgical | Post-IPO Debt | 15M |
| 6/2012 | just.me Inc | Debt Financing | 1.5M |
| 10/2013 | InspireMD | Post-IPO Debt | 10M |
| 6/2017 | Antares Pharma | Post-IPO Debt | 35M |
| 1/2020 | ChemoCentryx | Post-IPO Debt | 100M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 0 |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 2/2022 | Esme Learning Solutions | Venture Round | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 0 |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
